Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Gross Profit (2017 - 2024)

Historic Gross Profit for Avalo Therapeutics (AVTX) over the last 8 years, with Q3 2024 value amounting to -$465000.0.

  • Avalo Therapeutics' Gross Profit fell 412727.27% to -$465000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was -$96000.0, marking a year-over-year decrease of 17741.94%. This contributed to the annual value of $640000.0 for FY2023, which is 9562.15% down from last year.
  • Per Avalo Therapeutics' latest filing, its Gross Profit stood at -$465000.0 for Q3 2024, which was down 412727.27% from -$343000.0 recorded in Q2 2024.
  • In the past 5 years, Avalo Therapeutics' Gross Profit registered a high of $14.4 million during Q3 2022, and its lowest value of -$534000.0 during Q2 2022.
  • In the last 5 years, Avalo Therapeutics' Gross Profit had a median value of $276000.0 in 2022 and averaged $1.2 million.
  • Per our database at Business Quant, Avalo Therapeutics' Gross Profit soared by 316266.97% in 2022 and then plummeted by 412727.27% in 2024.
  • Over the past 5 years, Avalo Therapeutics' Gross Profit (Quarter) stood at $948000.0 in 2020, then crashed by 121.62% to -$205000.0 in 2021, then soared by 234.63% to $276000.0 in 2022, then soared by 186.96% to $792000.0 in 2023, then plummeted by 158.71% to -$465000.0 in 2024.
  • Its Gross Profit was -$465000.0 in Q3 2024, compared to -$343000.0 in Q2 2024 and -$80000.0 in Q1 2024.